Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy and new therapeutics are much needed. Profiling patient leukemia drug sensitivities ex vivo, we discovered that 44.4% of childhood and 16.7% of adult T-ALL cases exquisitely respond to dasatinib. Applying network-based systems pharmacology analyses to examine signal circuitry, we identified preTCR–LCK activation as the driver of dasatinib sensitivity and T-ALL-specific LCK dependency was confirmed in genome-wide CRISPR-Cas9 screens. Dasatinib-sensitive T-ALL exhibited high BCL-XL activity, low BCL2 activity and venetoclax resistance. Discordant sensitivity of T-ALL to dasatinib and venetoclax is strongly correlated with T-cell differentiation, particularly with the dynamic shift in LCK versus BCL2 activation. Finally, single-cell analysis identified leukemia heterogeneity in LCK and BCL2 signaling and T-cell maturation stage, consistent with dasatinib response. In conclusion, our results indicate that developmental arrest in T-ALL drives differential activation of preTCR–LCK and BCL2 signaling in this leukemia, providing unique opportunities for targeted therapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia
Leukemia Open Access 25 November 2023
-
PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
BMC Bioinformatics Open Access 28 June 2023
-
NetBID2 provides comprehensive hidden driver analysis
Nature Communications Open Access 04 May 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Data availability
Details of data access are provided on the permalink page on St. Jude Cloud (https://pecan.stjude.cloud/permalink/PGx-TALL). Briefly, genomic data are available at St. Jude Cloud (SJC-PB-1022), NCBI GEO (GSE158457) and EGA (EGAS00001004700). Genome-scale CRISPR-Cas9 screen result can be obtained at the DepMap Portal (https://depmap.org/portal/achilles) with raw data available at FigShare (https://figshare.com/articles/dataset/DepMap_19Q4_Public/11384241/3).
The TARGET T-ALL dataset is available in dbGAP (phs000218 and phs000464) and the microarray-based T-ALL expression profile is at NCBI GEO (GSE32215). Drug Bank database is at go.drugbank.com and KEGG pathway database is at genome.jp/kegg/pathway.html. The data that support the findings of this study are available from the corresponding authors upon request. Source data are provided with this paper.
Code availability
Codes for NetBID analysis and dasatinib biomarker score calculation are available at GitHub (https://github.com/jyyulab/dasatinib-TALL). Source data are provided with this paper.
References
Pui, C. H. et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J. Clin. Oncol. 33, 2938–2948 (2015).
Hunger, S. P. & Mullighan, C. G. Acute lymphoblastic leukemia in children. N. Engl. J. Med. 373, 1541–1552 (2015).
Slayton, W. B. et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of children’s oncology group trial AALL0622. J. Clin. Oncol. 36, 2306–2314 (2018).
Shen, S. et al. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.5868 (2020).
Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371, 1005–1015 (2014).
Raetz, E. A. & Teachey, D. T. T-cell acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program 2016, 580–588 (2016).
Girardi, T., Vicente, C., Cools, J. & De Keersmaecker, K. The genetics and molecular biology of T-ALL. Blood 129, 1113–1123 (2017).
Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211–1218 (2017).
McMahon, C. M. & Luger, S. M. Relapsed T cell ALL: current approaches and new directions. Curr. Hematol. Malig. Rep. 14, 83–93 (2019).
Nguyen, K. et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study. Leukemia 22, 2142–2150 (2008).
Teachey, D. T. & Hunger, S. P. Acute lymphoblastic leukaemia in 2017: immunotherapy for ALL takes the world by storm. Nat. Rev. Clin. Oncol. 15, 69–70 (2018).
Palomero, T. & Ferrando, A. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Clin. Lymphoma Myeloma 9, S205–S210 (2009).
Sarmento, L. M. & Barata, J. T. Therapeutic potential of Notch inhibition in T-cell acute lymphoblastic leukemia: rationale, caveats and promises. Expert Rev. Anticancer Ther. 11, 1403–1415 (2011).
Takebe, N., Nguyen, D. & Yang, S. X. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol. Ther. 141, 140–149 (2014).
Doody, R. S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N. Engl. J. Med. 369, 341–350 (2013).
Le Tourneau, C. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16, 1324–1334 (2015).
Sicklick, J. K. et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat. Med. 25, 744–750 (2019).
Letai, A. Functional precision cancer medicine-moving beyond pure genomics. Nat. Med. 23, 1028–1035 (2017).
Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. Nature 562, 526–531 (2018).
Lee, J. K. et al. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat. Genet. 50, 1399–1411 (2018).
Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920–926 (2018).
Frismantas, V. et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129, e26–e37 (2017).
Snijder, B. et al. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematol. 4, e595–e606 (2017).
Holleman, A. et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 351, 533–542 (2004).
Diouf, B. et al. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat. Med. 17, 1298–1303 (2011).
Putcha, P. et al. HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Res. 17, 149 (2015).
Alvarez, M. J. et al. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nat. Genet. 50, 979–989 (2018).
Piovan, E. et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 24, 766–776 (2013).
Kantarjian, H., Jabbour, E., Grimley, J. & Kirkpatrick, P. Dasatinib. Nat. Rev. Drug Discov. 5, 717–718 (2006).
Greuber, E. K., Smith-Pearson, P., Wang, J. & Pendergast, A. M. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat. Rev. Cancer 13, 559–571 (2013).
Nam, S. et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 65, 9185–9189 (2005).
Ceppi, P. et al. Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin. Mol. Cancer Ther. 8, 3066–3074 (2009).
Serafin, V. et al. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood 130, 2750–2761 (2017).
Laukkanen, S. et al. In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. Blood Cancer J. 7, e604 (2017).
Shi, Y. et al. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia. Haematologica 2019, 241026 (2020).
Kim, De,K. et al. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins. Haematologica 99, 85–93 (2014).
Du, X. et al. Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cells. Nature 558, 141–145 (2018).
Khatamian, A., Paull, E. O., Califano, A. & Yu, J. SJARACNe: a scalable software tool for gene network reverse engineering from big data. Bioinformatics 35, 2165–2166 (2019).
Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074–D1082 (2017).
Cotto, K. C. et al. DGIdb 3.0: a redesign and expansion of the drug–gene interaction database. Nucleic Acids Res. 46, D1068–D1073 (2017).
Klaeger, S. et al. The target landscape of clinical kinase drugs. Science 358, eaan4368 (2017).
Nyakeriga, A. M., Garg, H. & Joshi, A. TCR-induced T cell activation leads to simultaneous phosphorylation at Y505 and Y394 of p56(lck) residues. Cytometry A 81, 797–805 (2012).
Weber, E. W. et al. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 3, 711–717 (2019).
Williams, B. L. et al. Phosphorylation of Tyr319 in ZAP-70 is required for T-cell antigen receptor-dependent phospholipase C-γ1 and Ras activation. EMBO J. 18, 1832–1844 (1999).
Lee, K. C. et al. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia 24, 896–900 (2010).
Martin, M. W. et al. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J. Med. Chem. 49, 4981–4991 (2006).
Roth, G. J. et al. Nintedanib: from discovery to the clinic. J. Med. Chem. 58, 1053–1063 (2015).
Seki, M. et al. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat. Genet. 49, 1274–1281 (2017).
Rothenberg, E. V., Moore, J. E. & Yui, M. A. Launching the T-cell-lineage developmental programme. Nat. Rev. Immunol. 8, 9–21 (2008).
Mingueneau, M. et al. The transcriptional landscape of αβ T cell differentiation. Nat. Immunol. 14, 619–632 (2013).
Chonghaile, T. N. et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 4, 1074–1087 (2014).
Bellavia, D. et al. Combined expression of pTα and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc. Natl Acad. Sci. USA 99, 3788–3793 (2002).
dos Santos, N. R. et al. Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia. Blood 109, 3972–3981 (2007).
Yamasaki, S. & Saito, T. Molecular basis for pre-TCR-mediated autonomous signaling. Trends Immunol. 28, 39–43 (2007).
Chao, D. T. et al. Bcl-XL and Bcl-2 repress a common pathway of cell death. J. Exp. Med. 182, 821–828 (1995).
Gratiot-Deans, J., Merino, R., Nuñez, G. & Turka, L. A. Bcl-2 expression during T-cell development: early loss and late return occur at specific stages of commitment to differentiation and survival. Proc. Natl Acad. Sci. USA 91, 10685–10689 (1994).
Jeha, S. et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16. J. Clin. Oncol. 37, 3377–3391 (2019).
Zwaan, C. M. et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the innovative therapies for children with cancer consortium. J. Clin. Oncol. 31, 2460–2468 (2013).
Aplenc, R. et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children’s oncology group phase I consortium. J.Clin. Oncol. 29, 839–844 (2011).
Broniscer, A. et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin. Cancer Res. 19, 3050–3058 (2013).
Qian, M. et al. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Res. 27, 185–195 (2017).
Zhang, J. et al. Germline mutations in predisposition genes in pediatric cancer. New Engl. J. Med. 373, 2336–2346 (2015).
Rusch, M. et al. Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nat. Commun. 9, 3962 (2018).
Chen, X. et al. CONSERTING: integrating copy-number analysis with structural-variation detection. Nat. Methods 12, 527–530 (2015).
Wang, J. et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat. Methods 8, 652–654 (2011).
Pounds, S. et al. Reference alignment of SNP microarray signals for copy number analysis of tumors. Bioinformatics 25, 315–321 (2009).
Iwamoto, S., Mihara, K., Downing, J. R., Pui, C. H. & Campana, D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J. Clin. Invest. 117, 1049–1057 (2007).
Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017).
Dempster, J. M. et al. Extracting biological insights from the project Achilles genome-scale CRISPR screens in cancer cell lines. Preprint at: bioRxiv https://www.biorxiv.org/content/10.1101/720243v1 (2019).
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57, 289–300 (1995).
Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).
Smedley, D. et al. BioMart–biological queries made easy. BMC Genomics 10, 22 (2009).
Casero, D. et al. Long non-coding RNA profiling of human lymphoid progenitor cells reveals transcriptional divergence of B cell and T cell lineages. Nat. Immunol. 16, 1282–1291 (2015).
Wang, H. et al. Deep multiomics profiling of brain tumors identifies signaling networks downstream of cancer driver genes. Nat. Commun. 10, 3718 (2019).
Hornbeck, P. V. et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 40, D261–D270 (2011).
Zhang, J. et al. FLT3 pathway is a potential therapeutic target for PRC2-mutated T-cell acute lymphoblastic leukemia. Blood 132, 2520–2524 (2018).
Kiselev, V. Y. et al. SC3: consensus clustering of single-cell RNA-seq data. Nat. Methods 14, 483–486 (2017).
Acknowledgements
We thank the patients and families who participated in the clinical trials included in this study for donating specimens for research and the clinicians and research staff for assistance in sample collection, processing and curation. We also thank H. Williams and S. Zhou for their assistance in the drug-sensitivity profiling and phospho-proteomics profiling assays, respectively. We appreciate the thoughtful discussions with T. Sanda at the National University of Singapore. This work was in part supported by the National Institutes of Health (R35CA210030, R37CA36401, P50GM115279, R01GM118578, R01GM134382 and P30CA21765), the St. Baldrick’s Foundation and the Pan-Mass Challenge Team Crank and by the American Lebanese Syrian Associated Charities. Y. Gocho was supported by Tokyo Children’s Cancer Study Group overseas scholarship and Nippon Medical School, Japan.
Author information
Authors and Affiliations
Contributions
J.J.Y., J.Y., Y.G. and J. Hu designed the study and interpreted the results; Y.G., J. Hu, G.D., A.J., T.-N.L., J. Hunt, B.J., L.R., D.M. and B.S. performed the experiments; J.L., Wentao Yang, Wenjian Yang, H.S., X.H., K.H., S.P., L.S. and S.N. performed data analyses; N.V.D., Jingliao Zhang, L.S., K.R.C., Y.Z., K.R., H.W., E.J., W.S., B.E., E.P., G.R., M.L., J.E., Jinghui Zhang, J.P., H.C., S.P., M.V.R., H.I., X.Z., S.K., C.H.P., M.K., D.T., C.G.M., K.S. and W.E.E. contributed reagents, materials and analyses tools; J.J.Y., J.Y., Y.G., J. Hu and J.L. wrote the manuscript.
Corresponding authors
Ethics declarations
Competing interests
N.V.D. is a current employee of Genentech, Inc., a member of the Roche Group. S.N. is a current employee of Sema4 Inc. K.S. currently has funding from Novartis International AG and has previously consulted for Rigel Pharmaceuticals on topics unrelated to this manuscript. M.V.R. J.J.Y. and St. Jude receive investigator-initiated research funding from Servier for work unrelated to this manuscript. J.J.Y. and J.Y. are also named as co-inventors on a pending provisional US patent application filed by St. Jude based on this research.
Additional information
Peer review information Nature Cancer thanks Anna Bigas, Oliver Hantschel, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 ALL sensitivity to dasatinib and cytotoxic drugs.
a, Dasatinib LC50 distribution of all 352 ALL patient samples (including 307 B-ALL and 45 T-ALL samples). b, Of 86 pediatric B-ALL samples, 17.4% were sensitive to dasatinib, whereas 29.4% of 221 adult B-ALL samples were dasatinib-sensitive. c, Dasatinib LC50 reliably identified BCR-ABL1 B-ALL based on the receiving operating characteristic analysis. Dasatinib LC50 from 307 B-ALL (including 71 BCR-ABL B-ALL) was analyzed, and a LC50 cutoff at 80 nM achieved the optimal balance in sensitivity and specificity that distinguishes BCR-ABL samples from other B-ALLs. d, Examples of dose−response curve of dasatinib-sensitive or –resistant B-ALL and T-ALL. Sensitive and resistant cases are shown in red and blue, respectively. The sensitive B-ALL sample is BCR-ABL1-positive. For each patient at each drug concentration, cells were tested in duplicates. e, Of drugs tested for at least 30 cases in the T-ALL cohorts, LC50 of prednisolone and asparaginase exhibited a bimodal distribution whereas 6-MP and daunorubicin did not. N = 43, 38, 40, and 41 patients for prednisone, daunorubicin, 6-MP, and L-Asparaginase, respectively.
Extended Data Fig. 2 Comparison of T-ALL sensitivity to four ABL inhibitors.
a,b, PDX-derived leukemia cells were tested for sensitivity to each of the four inhibitors. A total of 11 cases were selected to represent dasatinib-sensitive vs resistant T-ALL and were xenografted in NSG mice to develop PDX. Mice were sacrificed once leukemia burden reached predefined endpoint, and human leukemia cells were harvested and subjected to drug sensitivity profiling ex vivo. Cells were incubated with increasing concentrations of each ABL inhibitor for 96 hours and cell viability was determined by flow cytometry as described in Methods. c, Dose-dependent cell death was determined for four ABL inhibitors in 8 T-ALL cell lines. HSB-2 (harbors TCR-LCK fusion), KOPT-K1 (harbors TCR-LMO2 fusion) and ALL-SIL (harbors ABL class fusion) were sensitive (LC50s are less than 0.05 nM) to both dasatinib and ponatinib but resistant to imatinib and nilotinib. For each leukemia case at each drug concentration, cells were tested in duplicates.
Extended Data Fig. 3 NetBID identified LCK and related genes for association with dasatinib sensitivity in T-ALL.
a, Activity of each gene was inferred using NetBID as described in Method and then compared between dasatinib-sensitive vs –resistant T-ALL with P value listed in the far right column. Top panel describes the expression ranking of all genes from the most highly expressed in dasatinib-sensitive cases on the left to the most highly expressed in resistant T-ALL on the right. Each gene in this pathway regulates a multitude of targets and their expression is indicated in two rows with positive-regulated target genes on the top and negatively regulated target genes at the bottom. In the case of LCK, it has 188 positive and 147 negative targets, each represented by a vertical line. Red lines indicate high expression in dasatinib sensitive T-ALL and blue lines indicate high expression in dasatinib-resistant cases. P-value was estimated using two-tailed t test. b, NetBID results for dasatinib target genes for association with dasatinib sensitivity in T-ALL. Dasatinib target gene list is derived from three databases Drug Bank, DGIdb, and chemical proteomic-based TKI target profiling, as shown in the Venn diagram in the left panel. Thirteen targets are commonly identified across three sources. NetBID analysis identified four of these 13 targets with a significantly higher activity (LCK, SRC, FYN and FGR) in dasatinib-sensitive samples compared to resistant cases, with P value for the differential gene activity listed in the right panel. P-value was estimated using two-tailed t test. c, PTCRA and LCK activity were compared between dasatinib-sensitive vs -resistant T-ALL samples with RNA-seq data in the pharmacotyping cohort (N = 15 and 30, respectively), P-value was estimated using two-tailed t test. Boxplots show summary of data in terms of the minimum, maximum, sample median, and the first and third quartiles. d,e, Gene networks used to infer PTCRA (d) and LCK (e) activity in NetBID. Each spoke represents a target gene (positively-regulated as red and negatively regulated as blue), with gene name indicated at the edge of each arrow. P-value was estimated using two-tailed t test. f, Running NetBID analysis using only pediatric cases in the discovery cohort (N = 12 and 15 patients for dasatinib-sensitive and –resistant, respectively), we re-estimated Z score for each gene which were then correlated with those from NetBID analysis using all T-ALL cases. Genes in the 30 biomarker panel are labeled and P value was estimated using Pearson correlation test.
Extended Data Fig. 4 LCK signaling is essential for dasatinib sensitivity in T-ALL.
a, Phospho-flow of LCK, ZAP70 and CD247 in dasatinib-sensitive vs –resistant T-ALL cell lines. Cells were treated with increasing concentrations of dasatinib for 1 h and then subjected to intracellular staining for phosphorylated LCK, ZAP70, and CD247, as described in Method. Phospho-protein was quantified by flow cytometry and normalized with samples not exposed to dasatinib as 100%. HSB-2 and KOPT-K1 (sensitive to dasatinib) is plotted in darker colors while CEM (resistant) is plotted in lighter colors. P-values were derived by ANOVA. b-d, LCK T316M mutation confers dasatinib resistance in KOPT-K1 cells. LCK T316M mutation was ectopically expressed in dasatinib-sensitive T-ALL KOPT-K1 cells. KOPT-K1 cells with wildtype LCK overexpression or empty vector control remained sensitive to dasatinib and ponatinib while overexpression of T316M LCK resulted in resistance to dasatinib (b) and ponatinib (c). Meanwhile, all three lines were resistant to ABL-specific inhibitor imatinib (d). For each leukemia sample at each drug concentration, cells were tested in duplicates. e. In KOPT-K1 cells with expressing wildtype LCK or empty vector control, LCK phosphorylation was inhibited by dasatinib in a dose-dependent manner, whereas LCK phosphorylation was unablated by dasatinib in cells expressing the T136M mutant LCK. Standard deviation is derived from biologically independent samples (N = 3) and is plotted as error bar. P value was estimated using Wilcoxon test. f,g, Genome-wide CRISPR screen identifies preTCR pathway genes as dependencies in T-ALL. F. LCK, ZAP70 and CD247 dependency score (x-axis) versus gene dependency probability (y-axis) demonstrates that a subset of T-ALL lines (blue, N = 3) show dependency on these preTCR pathway genes compared to all other cell lines screened (hematologic cancer cell lines in black, N = 73 and other cancer cell lines in gray, N = 613). Gene dependency of greater than 0.5 indicates a high probability that a cell line is dependent and corresponds to an approximate dependency score of −0.5. More negative gene dependency scores indicate greater effect on cell line survival. g, Gene dependency score (x-axis) versus gene dependency probability (y-axis) demonstrates that none of the T-ALL lines (blue, N = 3) show dependency on SRC kinase family genes (other than LCK shown in Fig. 2J) compared to all other cell lines screened (hematologic cancer cell lines in black, N = 73, and other cancer cell lines in gray, N = 613). Gene dependency of greater than 0.5 indicates a high probability that a cell line is dependent and corresponds to an approximate dependency score of -0.5. More negative gene dependency scores indicate greater effect on cell line survival.
Extended Data Fig. 5 Comparison of T-ALL sensitivity to three LCK inhibitors.
a,b, A total of 11 cases were selected to represent dasatinib-sensitive vs resistant T-ALL (N = 7 and 4 in Panels a and b, respectively) and were xenografted in NSG mice to develop PDX. Mice were sacrificed once leukemia burden reached predefined endpoint, and human leukemia cells were harvested and subjected to drug sensitivity profiling ex vivo. Cells were incubated with increasing concentrations of each LCK inhibitor for 96 hours and cell viability was determined by flow cytometry as described in Methods. c, Dose-dependent cell death was determined for two drugs in 8 T-ALL cell lines. For both drugs, HSB-2, (harbors TCR-LCK fusion) and KOPT-K1 (harbors TCR-LMO2 fusion) showed the highest sensitivity compared to ALL-SIL (harbors ABL class fusion) and other T-ALL cell lines. For each leukemia sample at each drug concentration, cells were tested in duplicates.
Extended Data Fig. 6 Biomarker model of dasatinib sensitivity in T-ALL.
a,b, A panel of 30 genes were selected as biomarkers from the top 461 driver genes in the NetBID analysis, as described in Methods. Dasatinib biomarker score was plotted for T-ALL cases, in the discovery cohort (a, N = 45) and in the validation cohort (b, N = 13). P value was estimated using two-tailed t test. c, Similarly, activity of each biomarker gene was estimated for the TARGET T-ALL cohort, from which an unsupervised clustering analysis was performed, as shown in the heatmap. Each row is a biomarker gene and each column represents a T-ALL case, with color discriminating the level of inferred gene activity. T-ALL subtype is indicated in the top row by color. d,e, Predicted LCK and PTCRA activity in the TARGET T-ALL cohort (N = 261). Activity of LCK and PTCRA was estimated for each T-ALL case from its RNA-seq data by NetBID algorithm. T-ALL subtypes were defined as previously described (Liu et al., 2017). f, In TARGET cohort, dasatinib biomarker score of cases in LMO2/LYL1 subtype showed a bimodal distribution. Cases with high biomarker score (dasatinib-sensitive, blue curve) exhibited a worse event-free survival compared to those with low biomarker score. P-value was estimated using Cox regression. g,h, Differential gene expression analyses of dasatinib sensitivity in T-ALL. In the discovery cohort, differences in gene expression between dasatinib-sensitive vs –resistant T-ALL was examined using the Limma method based on a linear model and results are presented as the volcano plot compared (g). Pathway analysis was performed with 254 genes that met the significance and effect size threshold (adjusted P < 1e-3 and log2 fold change >2), using the KEGG pathway database. P-value was inferred by Fisher exact test. I,j, Comparison of predicted dasatinib sensitivity in pediatric and adult T-ALL. i, Dasatinib biomarker score was significantly higher in pediatric cases than adults in the discovery cohort. This was also validated in an independent microarray-based T-ALL gene expression dataset (NCBI GSE32215) with 37 adult and 191 pediatric patient samples. j,T-ALL subtype was inferred from gene expression profile for cases in the GSE32215 dataset. Pediatric cases have a higher prevalence of the TAL1 and TAL2 subtypes whereas adults have a higher frequency of HOXA and LMO2/LYL1 subtypes. P value was estimated using two-tailed t test. Boxplots show summary of data in terms of the minimum, maximum, sample median, and the first and third quartiles.
Extended Data Fig. 7 SPI1-rearrangement is associated with developmental arrest and related to dasatinib sensitivity in T-ALL.
a, Dose-dependent cell death was determined for dasatinib using the ex vivo drug sensitivity assay as described in Methods. For each patient at each drug concentration, cells were tested in duplicates. b, Mouse Lin-Sca+Ckit + (LSK) cells were isolated from bone marrow and transduced lentivirally with SPI1 fusion gene or empty vector. After in vitro differentiation in the presence of OP9-DL1 cells and Il7 and Flt3 ligand, LSK cells were subjected to flow-cytometry analysis. TCF7-SPI1 expressing cells exhibited differentiation blockade at DN stage while the empty control cells were able to extensively differentiate to double positive and single positive stages.
Extended Data Fig. 8 Activity of dasatinib sensitivity-related genes across normal T cell developmental stages in mouse and human.
a,b, The activity of dasatinib sensitivity-related genes vary by T cell differentiation stage in mouse. RNA-based gene expression profile was obtained from the previously published dataset (Mingueneau et al. 2013), and NetBID was used to infer gene activity. a, NetBID-inferred activity of the 30 biomarker genes. Each mouse T cell developmental stage is represented as a column and each row indicates different genes in the biomarker panel. Gene activity is represented by color (low to high as blue to red). b, NetBID-inferred activity of PTCRA and LCK. Horizontal bars indicate the mean of gene activity for each T cell population. DN3-4 stages are highlighted in red. c–e, NetBID-inferred dasatinib biomarker score and activity of PTCRA and LCK in 10 normal human T cell developmental stages. RNA-based gene expression profile of human T cells was obtained from the previously published dataset (Casero et al. 2015). NetBID was used to infer LCK (d) and PTCRA (e) activity and biomarker score (c). Thy3 and Thy4 (approximately equivalent to DN3-4 and DN4 stages in mouse) are highlighted in red.
Extended Data Fig. 9 Relationship of LCK/BCL-XL/BCL2 activities with dasatinib and venetoclax sensitivity.
a, LCK activity was inversely correlated with venetoclax sensitivity in vitro. LCK activity was inferred from RNA-seq data using NetBID in the discovery cohort (P value was estimated using ANOVA). b-d, ETP T-ALL is associated with high BCL2 and low LCK/BCL-XL activity. BCL2/LCK/BCL-XL activity was estimated for cases in the TARGET cohort. Each case was annotated with ETP status. ETP cases exhibit low activity of LCK (b) and BCL-XL (d) while have high BCL2 activity (c). P-value was estimated using ANOVA. Boxplots show summary of data in terms of the minimum, maximum, sample median, and the first and third quartiles. e, NetBID analysis of venetoclax sensitivity in a subset of T-ALL case in the discovery cohort (N = 34 patients) identified 656 driver genes for drug response. Genes in the pre-TCR signaling pathway were most enriched in pathway analysis (downregulation linked to venetoclax sensitivity). f-m, scRNA-seq analysis identified intra-leukemia heterogeneity in LCK activity. T-ALL cells from SJ53 were incubated with dasatinib or vehicle for 4 days in vitro. scRNA-seq was then performed using viable cells from each group separately but transcription profiling data was pooled for subsequent analyses. Vehicle-treated cells mimicked naïve and sensitive to dasatnib whereas cells survived dasatinib exposure (dasatinib-treated) represented drug resistant cell population. f, tSNE visualization shows the distribution of dasatinib-treated (brick red) and naïve (green) cells in SJ65 and SJ53. Single cell RNA-seq and data analyses were described in Methods. g, LCK and BCL-XL activity was inferred by NetBID from single-cell RNA-seq of SJ66 and SJ53. P value were calculated using Pearson correlation, and color indicates cell populations (C1, C2, and C3 represented dasatinib resistant [red], responsive [green] and sensitive [blue] groups). h, Left panel, unsupervised clustering analysis of scRNA-seq of vehicle and dasatinib-treated T-ALL cells from SJ53. Each dot represent a single cell visualized in a two-dimensional projection by t-SNE. Three clusters (C1, C2, and C3, in red, green, and blue, respectively) were identified using k-means clustering. Right panel, cell composition of each cluster is visualized by stack plot with red and green indicating the % of cells from vehicle or dasatinib-treated samples. C1, C2, and C3 consisted of increasing proportion of naïve dasatinib-sensitive cells, representing populations with low, intermediate, and high sensitivity to dasatinib, respectively. i, Distribution of dasatinib biomarker score across three clusters. j, LCK activity was highest in cluster C3, intermediate in C2, and lowest in C1, paralleling the proportion of dasatinib-sensitive population. LCK activity is color-coded (from low to high, blue–red) on t-SNE plot. k, BCL2 activity was lowest in cluster C3, intermediate in C2, and highest in C1, paralleling the proportion of dasatinib-sensitive population. BCL2 activity is color-coded (from low to high, blue–red) on t-SNE plot. l, Inverse correlation of LCK and BCL2 activity at the single cell level in SJ53. Each dot represents a cell and color discriminate clusters C1, C2, and C3 (red, green, and blue, respectively). Correlation coefficient and P value were estimated using Pearson correlation. m, Differentiation stage of each population was projected by examining the gene expression signature characteristic of ETP or DN3/DN4 T cells. Signature was derived from differential expression analysis of mouse T cell expression dataset (Mingueneau et al., 2013). Heat map indicates the average of each gene (rows) for cells within each cluster (columns), after Z-normalization.
Extended Data Fig. 10 Schematic summary of main analyses, experiments, and major findings of this study.
Text is highlighted in red to indicate those unique to this report and advances compared to previous findings.
Supplementary information
Supplementary Information
Supplementary Figs. 1–4.
Supplementary Tables
Supplementary Tables 1–15.
Source data
Source Data Fig. 1
Statistical source data.
Source Data Fig. 2
Statistical source data.
Source Data Fig. 3
Statistical source data.
Source Data Fig. 4
Statistical source data.
Source Data Fig. 6
Statistical source data.
Source Data Fig. 7
Statistical source data.
Source Data Fig. 8
Statistical source data.
Source Data Extended Data Fig. 1
Statistical source data.
Source Data Extended Data Fig. 2
Statistical source data.
Source Data Extended Data Fig. 3
Statistical source data.
Source Data Extended Data Fig. 4
Statistical source data.
Source Data Extended Data Fig. 5
Statistical source data.
Source Data Extended Data Fig. 6
Statistical source data.
Source Data Extended Data Fig. 7
Statistical source data.
Source Data Extended Data Fig. 8
Statistical source data.
Source Data Extended Data Fig. 9
Statistical source data.
Rights and permissions
About this article
Cite this article
Gocho, Y., Liu, J., Hu, J. et al. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer 2, 284–299 (2021). https://doi.org/10.1038/s43018-020-00167-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-020-00167-4
This article is cited by
-
PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
BMC Bioinformatics (2023)
-
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
Journal of Hematology & Oncology (2023)
-
The identification of metabolites from gut microbiota in NAFLD via network pharmacology
Scientific Reports (2023)
-
NetBID2 provides comprehensive hidden driver analysis
Nature Communications (2023)
-
Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia
Leukemia (2023)
